Evidence map›Paper›PMID 38830399›Full record

ReviewProstaglandins & other lipid mediators2024

Glucocorticoid resistance remodels liver lipids and prompts lipogenesis, eicosanoid, and inflammatory pathways.

Genesee J Martinez, Zachary A Kipp, Wang-Hsin Lee, Evelyn A Bates, Andrew J Morris, Joseph S Marino, Terry D Hinds

Abstract readReview
In one paragraph

Review in Prostaglandins & other lipid mediators, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Genesee J MartinezDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA; Drug & Disease Discovery D3 Research Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Zachary A KippDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA; Drug & Disease Discovery D3 Research Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Wang-Hsin LeeDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA; Drug & Disease Discovery D3 Research Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Evelyn A BatesDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA; Drug & Disease Discovery D3 Research Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Andrew J MorrisDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, and Central Arkansas Veterans Affairs Healthcare System, Little Rock, AR 72205, USA.
Joseph S MarinoDepartment of Applied Physiology, Health, and Clinical Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, USA.
Terry D HindsDepartment of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, USA; Drug & Disease Discovery D3 Research Center, University of Kentucky College of Medicine, Lexington, KY, USA; Markey Cancer Center, University of Kentucky, Lexington, KY, USA; Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, USA. Electronic address: Terry.Hinds@uky.edu.

Funding

Novel Liver Signaling Pathways Controlling AdiposityR01DK121797 · NIDDK · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI HINDS, TERRY D · 2020 to 2024
$2.2M
Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawalR01DA058933 · NIDA · UNIVERSITY OF KENTUCKY · PI Cassandra D Gipson-Reichardt, Terry D Hinds · 2023 to 2026
$2.0M
Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic DysfunctionF31HL170972 · NHLBI · UNIVERSITY OF KENTUCKY · PI Zachary A Kipp · 2023 to 2026
$105k
BLRD Research Career Scientist Award ApplicationIK6BX006469 · VA · CENTRAL ARKANSAS VETERANS HLTHCARE SYS · PI MORRIS, ANDREW J · 2024 to 2025
–
BLRD VA I01 BX004671BLRD VA IK6 BX006469NHLBI NIH HHS F31 HL170972NIDA NIH HHS R01 DA058933NIDDK NIH HHS R01 DK121797NIMHD NIH HHS L32 MD009154NIMHD NIH HHS L32 MD011984
6 · The paper itself

Abstract

We have previously demonstrated that the glucocorticoid receptor β (GRβ) isoform induces hepatic steatosis in mice fed a normal chow diet. The GRβ isoform inhibits the glucocorticoid-binding isoform GRα, reducing responsiveness and inducing glucocorticoid resistance. We hypothesized that GRβ regulates lipids that cause metabolic dysfunction. To determine the effect of GRβ on hepatic lipid classes and molecular species, we overexpressed GRβ (GRβ-Ad) and vector (Vec-Ad) using adenovirus delivery, as we previously described. We fed the mice a normal chow diet for 5 days and harvested the livers. We utilized liquid chromatography-mass spectrometry (LC-MS) analyses of the livers to determine the lipid species driven by GRβ. The most significant changes in the lipidome were monoacylglycerides and cholesterol esters. There was also increased gene expression in the GRβ-Ad mice for lipogenesis, eicosanoid synthesis, and inflammatory pathways. These indicate that GRβ-induced glucocorticoid resistance may drive hepatic fat accumulation, providing new therapeutic advantages.

Indexed as

EicosanoidsGlucocorticoidsInflammationLipogenesisLiverReceptors, GlucocorticoidAnimalsLipid MetabolismMaleMiceMice, Inbred C57BLEicosanoidsglucocorticoid receptor betaGlucocorticoidsReceptors, GlucocorticoidGlucocorticoid receptorGRβLipidomeMASLDMetabolic syndromeNonalcoholic fatty liver disease

Identifiers

PMID38830399
PMCPMC11199073

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.